Business Wire·May 7, 2026, 4:05 PM ET

Sensus Healthcare Reports First Quarter 2026 Financial Results and Business Highlights

SRTS

Sensus Healthcare reported Q1 2026 revenue of $3.4 million, a decrease from $8.3 million in the same period in 2025, primarily due to the absence of sales to its largest historical customer.
Revenue excluding sales to the largest customer increased to $3.4 million from $2.7 million in the prior-year period, reflecting customer base diversification.
The company shipped 14 SRT systems in Q1 2026 (10 direct sales, 4 under Fair Deal Agreement or rental), compared to 30 systems shipped in Q1 2025.
Dedicated CPT codes for SRT effective January 1, 2026, have provided reimbursement certainty, leading to increased inquiry levels, stronger sales pipelines, and greater engagement from dermatology practices.
The Fair Deal Agreement program expanded to 18 active sites with 9 pending as of March 31, 2026, with treatment volumes rising 8% year-over-year.
Management launched Sensus Healthcare Financial Services to support customer acquisition and introduced Sensus Link to enhance operating capabilities for the installed base.
General and administrative, selling, marketing, and research expenses decreased compared to the prior year due to lower professional fees, reduced tradeshow costs, and decreased lobbying costs.
Adjusted EBITDA for the quarter was a negative $4.2 million, compared to a negative $2.5 million in the prior-year period.
The company reported a net loss of $2.6 million, or $0.16 per share, matching the net loss from the same period in 2025.
Sensus Healthcare ended the quarter with $18.3 million in cash, no debt, and prepaid inventory of $2.5 million.
CEO Joseph Sardano outlined five 2026 priorities: education, accelerating adoption, expanding recurring revenue, broadening commercial reach, and driving toward profitability.